On the basis of the results of previous national and international trials and studies, the Renal Tumour Study Group of the International Society of Paediatric Oncology (SIOP–RTSG) has developed a new study protocol for paediatric renal tumours: the UMBRELLA SIOP–RTSG 2016 protocol (the UMBRELLA protocol). Currently, the overall outcomes of patients with Wilms tumour are excellent, but subgroups with poor prognosis and increased relapse rates still exist. The identification of these subgroups is of utmost importance to improve treatment stratification, which might lead to reduction of the direct and late effects of chemotherapy. The UMBRELLA protocol aims to validate new prognostic factors, such as blastemal tumour volume and molecular markers, to further improve outcome. To achieve this aim, large, international, high-quality databases are needed, which dictate optimization and international harmonization of specimen handling and comprehensive sampling of biological material, refine definitions and improve logistics for expert review. To promote broad implementation of the UMBRELLA protocol, the updated SIOP–RTSG pathology and molecular biology protocol for Wilms tumours has been outlined, which is a consensus from the SIOP–RTSG pathology panel.

根据先前的国家和国际试验研究结果，国际小儿肿瘤学会肾脏肿瘤研究小组（SIOP-RTSG）已开发出一种针对小儿肾肿瘤的新研究方案：UMBRELLA SIOP-RTSG 2016方案（UMBRELLA协议）。目前，Wilms肿瘤患者的总体预后良好，但预后差和复发率高的亚组仍然存在。这些亚组的鉴定对于改善治疗分层至关重要，这可能导致化学疗法的直接作用和晚期作用降低。UMBRELLA协议旨在验证新的预后因素，例如母细胞瘤的体积和分子标记，以进一步改善预后。为了实现这一目标，需要大型的国际高质量数据库，它要求对标本处理和生物材料的全面采样进行优化和国际协调，完善定义并改善后勤工作，以供专家审查。为了促进UMBRELLA协议的广泛实施，已概述了针对Wilms肿瘤的更新的SIOP-RTSG病理学和分子生物学协议，这是SIOP-RTSG病理学专家组的共识。